Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population

Pharmacogenetics and Genomics

Volumn 26, Issue 2, 2016, Pages 100-102

  Gutierrez Camino, Angela ^a   Martin Guerrero, Idoia ^a   Lopez Lopez, Elixabet ^a   Echebarria Barona, Aizpea ^c   Zabalza, Iñaki ^d   Ruiz, Irune ^e   Guerra Merino, Isabel ^f   Garcia Orad, Africa ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d HOSPITAL DE GALDAKAO   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

Author keywords

CEP72; Neurotoxicity; RS924607; Vincristine

Indexed keywords

ASPARAGINASE; CELL PROTEIN; CEP72 PROTEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A5; DAUNORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE; CEP72 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; DRUG INDUCED DISEASE; FEMALE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENOTYPE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEXT GENERATION SEQUENCING; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SPANIARD; CHEMICALLY INDUCED; GENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SPAIN;

CHILD; GENOTYPE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PERIPHERAL NERVOUS SYSTEM DISEASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SPAIN; VINCRISTINE;

EID: 84983171089     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000191     Document Type: Article

References (7)

1. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56:361-367.
2. Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015; 313:815-823.
3. Ceppi F, Langlois-Pelletier C, Gagné V, Rousseau J, Ciolino C, De Lorenzo S, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 2014; 15:1105-1116.
4. Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008; 50:769-771.
5. Moore AS, Norris R, Price G, Nguyen T, Ni M, George R, et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limitedsampling, population modelling approach. J Paediatr Child Health 2011; 47:875-882.
6. Hartman A, van Schaik RH, van der Heiden IP, Broekhuis MJ, Meier M, den Boer ML, et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk Res 2010; 34:154-159.
7. Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004; 76:220-229.